MediNavi Valuation

Is MDQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MDQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MDQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MDQ's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MDQ?

Key metric: As MDQ is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MDQ. This is calculated by dividing MDQ's market cap by their current book value.
What is MDQ's PB Ratio?
PB Ratio	n/a
Book	€39.37k
Market Cap	€379.68k

MDQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does MDQ's PB Ratio compare to its peers?

The above table shows the PB ratio for MDQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	0.9x
HT6 Learning 2 Sleep L2S	0.03x	n/a	€85.9k
MF6 MagForce	0.01x	n/a	€366.9k
V3V VITA 34	3.2x	74.8%	€73.9m
EIF MedNation	0.4x	n/a	€4.2m
MDQ MediNavi	n/a	n/a	€379.7k

Price-To-Book vs Peers: Insufficient data to calculate MDQ's Price-To-Book Ratio vs. peers for valuation analysis.

Price to Book Ratio vs Industry

How does MDQ's PB Ratio compare vs other companies in the DE Healthcare Industry?

1 Company	Price / Book	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: Insufficient data to calculate MDQ's Price-To-Book Ratio vs. industry for valuation analysis.

Price to Book Ratio vs Fair Ratio

What is MDQ's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MDQ PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	n/a
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MDQ's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$50.67

-2.6%

-18.8%

Fagron

€1.4b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.54

-2.3%

6.7%

Shandong Weigao Group Medical Polymer

HK$20.4b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

-7.9%

-41.0%